The roles of PPARs in human diseases

被引：13
作者：
Li, Jingjing [1 ]
Liu, Yi-Ping [1 ]
机构：
[1] Sichuan Agr Univ, Farm Anim Genet Resources Explorat & Innovat Key, Chengdu 611130, Sichuan, Peoples R China
来源：
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2018年 / 37卷 / 07期
关键词：
PPARs; cancers; atherosclerosis; type 2 diabetes mellitus; ACTIVATED-RECEPTOR-GAMMA; MODULATOR SPPARM-ALPHA; INSULIN-RESISTANCE; NITRIC-OXIDE; DIABETES-MELLITUS; LIPID-METABOLISM; CLINICAL-TRIALS; SKELETAL-MUSCLE; TISSUE FACTOR; GENE-THERAPY;
D O I：
10.1080/15257770.2018.1475673
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Peroxisome proliferator-activated receptors (PPARs), as members of nuclear hormone receptor superfamily, can be activated by binding natural or synthetic ligands. The use of related ligands has revealed many potential roles for PPARs in the pathogenesis of some human metabolic disorders and inflammatory-related disease. Based on the previous studies, this review primarily concluded the current progress of knowledge regarding the specific biological activity of PPARs in cancers, atherosclerosis, and type 2 diabetes mellitus, providing a foundation for the potential therapeutic use of PPAR ligands in human diseases.
引用
收藏
页码：361 / 382
页数：22
相关论文
共 149 条
[1]   Peroxisome proliferator-activated receptor β/δ regulates very low density lipoprotein production and catabolism in mice on a Western diet [J].
Akiyama, TE ;
Lambert, G ;
Nicol, CJ ;
Matsusue, K ;
Peters, JM ;
Brewer, HB ;
Gonzalez, FJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (20) :20874-20881
[2]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[3]  
2-S
[4]   Progress and prospects: Gene therapy clinical trials (part 2) [J].
Alton, Eric ;
Ferrari, Stefano ;
Griesenbach, Uta .
GENE THERAPY, 2007, 14 (22) :1555-1563
[5]   Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-α gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes -: The STOP-NIDDM trial [J].
Andrulionyte, Laura ;
Kuulasmaa, Teemu ;
Chiasson, Jean-Louis ;
Laakso, Markku .
DIABETES, 2007, 56 (04) :1181-1186
[6]  
Annese V., 2012, PPAR RES, V4, P195
[7]  
[Anonymous], 2016, FACT SHEET DIABATE
[8]   PPAR Medicines and Human Disease: The ABCs of It All [J].
Apostoli, Anthony J. ;
Nicol, Christopher J. B. .
PPAR RESEARCH, 2012, 2012
[9]   Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia [J].
Arai, Hidenori ;
Yamashita, Shizuya ;
Yokote, Koutaro ;
Araki, Eiichi ;
Suganami, Hideki ;
Ishibashi, Shun .
ATHEROSCLEROSIS, 2017, 261 :144-152
[10]   PPARγ Agonists and Vascular Risk Factors: Potential Effects on Cardiovascular Disease [J].
Asnani, Sunil ;
Theuma, Pierre ;
Fonseca, Vivian A. .
METABOLIC SYNDROME AND RELATED DISORDERS, 2003, 1 (01) :23-32
12345678910